Form 4: Corbus Pharmaceuticals Director Equity Grant

Director Rachelle Jacques received a grant of 3,800 restricted stock units and 12,300 stock options.

Summary

• Director Rachelle Jacques was granted 3,800 restricted stock units (RSUs) on May 19, 2026.
• The RSUs vest 100% on the one-year anniversary of the grant date.
• A stock option grant for 12,300 shares was also issued with an exercise price of $9.15.
• The stock options vest 100% on the one-year anniversary of the grant date.
• Following these transactions, the director holds 11,383 shares of common stock and 12,300 derivative securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedule ensures retention of board leadership.

Negatives

• Issuance of equity results in minor dilution to existing shareholders.

Risks

• Market volatility affecting the value of the granted equity.
• Performance risks associated with the company's ability to meet milestones required for the underlying stock value to appreciate.

Future Outlook

The equity grants are subject to a one-year vesting period, indicating a commitment to the company's long-term strategic direction.

Management Comments

• The grants were made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a one-year cliff vesting schedule is consistent with standard corporate governance practices for non-employee directors in the pharmaceutical industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs on May 19, 2027.
• Vesting of stock options on May 19, 2027.

Key Dates

Keywords

Corbus Pharmaceuticals, CRBP, Form 4, Insider Trading, Equity Compensation, Director Compensation